Previous close | 92.30 |
Open | N/A |
Bid | 85.80 |
Ask | 93.00 |
Strike | 220.00 |
Expiry date | 2026-01-16 |
Day's range | 92.30 - 92.30 |
Contract range | N/A |
Volume | |
Open interest | 10 |
The FDA grants orphan drug and rare pediatric disease designations to LBPH's lead pipeline drug for the treatment of Dravet Syndrome.
With this approval, JNJ's Rybrevant is now approved for a total of four indications in the United States.
Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.